 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...4546474849505152535455...208209» |
- ||| SHR-1819 / Jiangsu Hengrui Pharma
Enrollment open, Enrollment change: SHR-1819-204: A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis (clinicaltrials.gov) - Feb 26, 2025
P1/2, N=50, Recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting | N=36 --> 50
- |||| Enrollment open: A Trial of HRS-2189 in Combination With Fluvastatin (clinicaltrials.gov) - Feb 26, 2025
P1/2, N=300, Recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
Not yet recruiting --> Recruiting | N=36 --> 50 Not yet recruiting --> Recruiting
- ||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment open: The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution (clinicaltrials.gov) - Feb 26, 2025
P1, N=120, Recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Retrospective data, Review, Journal: The Predictive Role of the Gleason Score in Determining Prognosis to Systematic Treatment in Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Feb 26, 2025
In the Gleason score <8 subgroup, only darolutamide + docetaxel + ADT (HR 0.49, 95% CI 0.29-0.81) and apalutamide + ADT (HR 0.67, 95% CI 0.46-0.98) improved OS. ARSI combination therapy is effective for mCSPC patients with Gleason score ?8, but further investigation is needed to confirm its efficacy in patients with Gleason score <8.
- ||||| SHR-1826 / Jiangsu Hengrui Pharma
New P2 trial: A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC (clinicaltrials.gov) - Feb 26, 2025
P2, N=300, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Microsatellite instability, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Immunotherapy-induced microsatellite instability status shift in recurrent perihilar cholangiocarcinoma: A case report. (Pubmed Central) - Feb 25, 2025
MSI heterogeneity is not only rare but potentially has implications for treatment personalization and prognosis in patients with cholangiocarcinoma. This case highlights the dynamic changes in tumor characteristics during immunotherapy.
- || AiRuiKa (camrelizumab) / HLB Bio Group
Clinical, Journal, Combination therapy, Metastases: Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial. (Pubmed Central) - Feb 25, 2025
P3
Among patients with early or locally advanced triple-negative breast cancer, the addition of camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response. ClinicalTrials.gov Identifier: NCT04613674.
- GSK5784283 / GSK, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
AI-guided Generation and Development of HXN-1011, A Highly Potent Anti-TSLP Biparatopic Antibody (Room 2022/2024 (West Building, Level 2), Moscone Center; Poster Board # 812) - Feb 24, 2025 - Abstract #ATS2025ATS_8030;
It has great potential to significantly enhance clinical efficacy and expand to other inflammatory diseases beyond asthma/COPD. Preclinical and IND-enabling studies of HXN-1011 are currently underway.
- | Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Trial completion date: Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies (clinicaltrials.gov) - Feb 24, 2025
P2, N=52, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Preclinical and IND-enabling studies of HXN-1011 are currently underway. Trial completion date: Sep 2024 --> Sep 2025
- |||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open, IO biomarker: SHR-A1811-310: A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations (clinicaltrials.gov) - Feb 24, 2025
P3, N=300, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial completion date: Sep 2024 --> Sep 2025 Not yet recruiting --> Recruiting
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Journal, HEOR, PD(L)-1 Biomarker, Cost-effectiveness: Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer. (Pubmed Central) - Feb 24, 2025
T-DXd provides substantial therapeutic benefit for NSCLC patients with HER2 mutations who have had previous treatment but is not deemed cost-effective in either the US or China when compared to docetaxel, nivolumab, and pyrotinib. Price reduction is perhaps the main way to make T-DXd cost-effective.
- | ursodeoxycholic acid / Generic mfg.
New P2 trial: PD-L1 Inhibitor + RT (clinicaltrials.gov) - Feb 24, 2025
P2, N=70, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: Herombopag for Chemotherapy-induced Thrombocytopenia (clinicaltrials.gov) - Feb 24, 2025
P2, N=50, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Price reduction is perhaps the main way to make T-DXd cost-effective. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Dec 2024
- ||| AiTan (rivoceranib) / Elevar Therapeutics, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Trial completion, Trial completion date, Monotherapy: FZPL-II-201: A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients (clinicaltrials.gov) - Feb 23, 2025
P2, N=100, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Dec 2024 Recruiting --> Completed | Trial completion date: Mar 2022 --> Nov 2024
- || AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal, Metastases: A Randomised, Multicentre, Phase II Trial of Camrelizumab with or without Metastasis-directed Stereotactic Body Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma. (Pubmed Central) - Feb 23, 2025
P2
Recruiting --> Completed | Trial completion date: Mar 2022 --> Nov 2024 Our study did not meet its primary endpoint of superior ORR of unirradiated lesions with the addition of MDT to Cam in patients with R/M-NPC.
- sonesitatug vedotin (AZD0901) / AstraZeneca
CLARITY-Gastric 01: a randomized Phase 3 study of AZD0901 in 2L+ advanced gastric/gastroesophageal junction cancers (Room 8 | International Conference Room, 3F, Kobe International Conference Center) - Feb 22, 2025 - Abstract #JSMO2025JSMO_1223;
- ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Effects of ivarmacitinib on itch and sleep improvements and their impact on quality of life in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of a phase III trial () - Feb 21, 2025 - Abstract #AAD2025AAD_2967;
P3
Our study did not meet its primary endpoint of superior ORR of unirradiated lesions with the addition of MDT to Cam in patients with R/M-NPC. Ivarmacitinib treatment improves both itch and sleep, and these improvements are associated with better QoL in patients with moderate-to-severe AD.
- ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Ivarmacitinib in patients with moderate-to-severe atopic dermatitis, stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial () - Feb 21, 2025 - Abstract #AAD2025AAD_2961;
Ivarmacitinib demonstrates substantial benefits across subgroups of M-SAD patients. Switching from placebo to ivarmacitinib also provides considerable benefits across patient subgroups.
- vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
Comparison of patient-reported outcomes in patients achieving complete versus near-complete skin clearance following Vunakizumab treatment: A post-hoc analysis of a phase III trial () - Feb 21, 2025 - Abstract #AAD2025AAD_2941;
P3
The mean DLQI score and itch NRS score were lower, but the mean SF-36 MCS and SF-36 PCS were higher at some time points in the PASI 100 group than in the PASI 90-99 group (P<0.05). Conclusion Patients with complete skin clearance following Vunakizumab treatment showed improved quality of life, reduced pruritus, and enhanced mental health compared to those with near-complete clearance.
- vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
Early response to vunakizumab at week 2 predicts favorable long-term efficacy in patients with moderate-to-severe plaque psoriasis: a post-hoc analysis of a phase III, randomized controlled trial () - Feb 21, 2025 - Abstract #AAD2025AAD_2938;
P3
Conclusion Patients with complete skin clearance following Vunakizumab treatment showed improved quality of life, reduced pruritus, and enhanced mental health compared to those with near-complete clearance. Patients with moderate-to-severe plaque psoriasis who achieved early response to vunakizumab at W2 significantly increase the likelihood of improved long-term treatment response.
- ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with prior systemic therapy: a post-hoc analysis of a phase III trial () - Feb 21, 2025 - Abstract #AAD2025AAD_2937;
P3
Patients with moderate-to-severe plaque psoriasis who achieved early response to vunakizumab at W2 significantly increase the likelihood of improved long-term treatment response. Ivarmacitinib demonstrates a good efficacy and safety profile in moderate-to-severe atopic dermatitis patients with prior systemic therapy.
- ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Efficacy and safety of Ivarmacitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies () - Feb 21, 2025 - Abstract #AAD2025AAD_2931;
Ivarmacitinib demonstrates a good efficacy and safety profile in moderate-to-severe atopic dermatitis patients with prior systemic therapy. Ivarmacitinib demonstrates rapid and consistent efficacy and is well-tolerated in M-SAD patients with comorbid allergies.
- vunakizumab (SHR-1314) / Jiangsu Hengrui Pharma
Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis across different regions of China: a post-hoc analysis of a phase III, randomized controlled trial () - Feb 21, 2025 - Abstract #AAD2025AAD_2930;
P3
Ivarmacitinib demonstrates rapid and consistent efficacy and is well-tolerated in M-SAD patients with comorbid allergies. The efficacy and safety of vunakizumab are not affected by different regions of China in patients with moderate-to-severe plaque psoriasis.
- ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Early response to Ivarmacitinib and its impact on long-term efficacy in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of a phase III trial () - Feb 21, 2025 - Abstract #AAD2025AAD_2927;
P3
The efficacy and safety of vunakizumab are not affected by different regions of China in patients with moderate-to-severe plaque psoriasis. Early response to Ivarmacitinib at W4 yields better long-term efficacy in patients with moderate-to-severe AD.
- ivarmacitinib (SHR0302) / Jiangsu Hengrui Pharma, Arcutis
Efficacy and safety of ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of adult with severe alopecia areata (AA): a randomized, double-blind, placebo-controlled phase 3.. (Chapin Theater - Level III) - Feb 21, 2025 - Abstract #AAD2025AAD_2168;
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P2 trial: A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP (clinicaltrials.gov) - Feb 21, 2025
P2, N=80, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
- || trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P1/2 trial, Platinum sensitive: A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Feb 21, 2025
P1/2, N=50, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment change, Trial withdrawal: Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach (clinicaltrials.gov) - Feb 21, 2025
P2, N=0, Withdrawn, Sponsor: Peking University
Early response to Ivarmacitinib at W4 yields better long-term efficacy in patients with moderate-to-severe AD. N=41 --> 0 | Recruiting --> Withdrawn
- || recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
New P1 trial: Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers (clinicaltrials.gov) - Feb 20, 2025
P1, N=46, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | oxaliplatin / Generic mfg., AiRuiKa (camrelizumab) / HLB Bio Group, docetaxel / Generic mfg.
Journal, Real-world evidence: Camrelizumab combined with neoadjuvant docetaxel, oxaliplatin, and S1 as induction therapy for locally advanced esophageal squamous cell cancer: a real-world single-center cohort study. (Pubmed Central) - Feb 20, 2025
While our real-world data suggest potential benefits of neoadjuvant camrelizumab plus chemotherapy in locally advanced ESCC, the absence of a control group limits the generalizability of these findings. Further randomized studies are needed to validate these results.
- | AiTan (rivoceranib) / HLB Bio Group
Retrospective data, Journal: Analysis of the correlation between the dose exposure intensity and apatinib in advanced gastric cancer: a retrospective cohort study. (Pubmed Central) - Feb 20, 2025
The efficacy of apatinib in advanced gastric cancer was significantly positively correlated with dose exposure intensity, and HDEI can prolong PFS and OS. Early application of low-dose apatinib (250 mg/d) can improve patients' tolerability, and the adverse reactions are controllable.
- || 5-fluorouracil / Generic mfg.
P2 data, Journal: Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial. (Pubmed Central) - Feb 19, 2025
P2
This work demonstrates feasibility and safety for immunochemotherapy in the neoadjuvant setting for OSCC. This study was registered at ClinicalTrials.gov (NCT04649476).
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Journal, Monotherapy: [18F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study. (Pubmed Central) - Feb 19, 2025
P2
This study was registered at ClinicalTrials.gov (NCT04649476). The metabolic parameters of
- | oxaliplatin / Generic mfg., AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Retrospective data, Journal, Checkpoint inhibition: Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective cohort study. (Pubmed Central) - Feb 19, 2025
The treatment protocol combined ICIs, anti-angiogenic therapy (specifically apatinib), and chemotherapy (S-1 with oxaliplatin)...Only one patient experienced a grade 4 TRAE (immune-related hepatitis), while the most common grade 3 TRAEs included thrombocytopenia, elevated aminotransferase levels, and neutropenia. The combination of neoadjuvant chemotherapy, anti-angiogenic therapy, and ICIs has proven effective in treating LAGC patients, achieving high pCR rates and favorable survival outcomes while maintaining an acceptable safety profile.
- || HRS-9821 / Jiangsu Hengrui Pharma
Enrollment change, Trial completion date, Trial primary completion date: Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients (clinicaltrials.gov) - Feb 19, 2025
P1, N=134, Recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
The combination of neoadjuvant chemotherapy, anti-angiogenic therapy, and ICIs has proven effective in treating LAGC patients, achieving high pCR rates and favorable survival outcomes while maintaining an acceptable safety profile. N=80 --> 134 | Trial completion date: Sep 2023 --> Sep 2025 | Trial primary completion date: Jul 2023 --> Jul 2025
- | Epidaza (chidamide) / Chipscreen, Itari (linperlisib) / Shanghai YingLi Pharma
Trial completion date, Trial primary completion date: Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma (clinicaltrials.gov) - Feb 19, 2025
P2, N=33, Recruiting, Sponsor: The First Affiliated Hospital of Xiamen University
N=80 --> 134 | Trial completion date: Sep 2023 --> Sep 2025 | Trial primary completion date: Jul 2023 --> Jul 2025 Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2027
- |||||||| AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
New P3 trial: The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Feb 18, 2025
P3, N=90, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
Confronting Barriers in HER2-Positive Metastatic Breast Cancer: Insights from a Phase II Trial of Inetetamab, Pyrotinib, and Chemotherapy () - Feb 18, 2025 - Abstract #SGBCC2025SG_BCC_178;
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Updated efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate, in heavily pretreated advanced solid tumors with HER2-expression or mutations: a global, multicenter, phase 1 study () - Feb 18, 2025 - Abstract #SGBCC2025SG_BCC_175;
- | Retrospective data, Journal: Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis. (Pubmed Central) - Feb 18, 2025
Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2027 The currently used targeted drug therapies for RR-DTC can significantly improve clinical outcomes, and the new drug apatinib demonstrates promise for potentially superior performance.
- | AiTan (rivoceranib) / HLB Bio Group, Lysodren (mitotane) / Perrigo Company
New P2 trial: Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma (clinicaltrials.gov) - Feb 18, 2025
P2, N=28, Not yet recruiting, Sponsor: West China Hospital
- GSK5784283 / GSK
Enrollment open: Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study (clinicaltrials.gov) - Feb 18, 2025
P2, N=8, Recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
The currently used targeted drug therapies for RR-DTC can significantly improve clinical outcomes, and the new drug apatinib demonstrates promise for potentially superior performance. Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Trial primary completion date: Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer (clinicaltrials.gov) - Feb 18, 2025
P2, N=30, Recruiting, Sponsor: First Affiliated Hospital of Zhejiang University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2023 --> May 2025
- | AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
New P2 trial: Exploration of Treatment Effect of Novel Hormone Therapy Combined with Local Treatment Based on PSMA PET/CT Evaluation in MHSCP Patients (clinicaltrials.gov) - Feb 18, 2025
P2, N=192, Not yet recruiting, Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- | Keytruda (pembrolizumab) / Merck (MSD), plinabulin (BPI 2358) / BeyondSpring
Enrollment closed: Pembrolizumab in Combination with Plinabulin and Docetaxel for Metastatic NSCLC After ICIs (KeyPemls-004) (clinicaltrials.gov) - Feb 18, 2025
P2, N=47, Active, not recruiting, Sponsor: Peking Union Medical College Hospital
Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2023 --> May 2025 Recruiting --> Active, not recruiting
- |||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial primary completion date: A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 18, 2025
P3, N=425, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2024 --> Jul 2026
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05) (clinicaltrials.gov) - Feb 17, 2025
P2, N=33, Recruiting, Sponsor: First Affiliated Hospital of Zhejiang University
- | AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Journal: Short-term efficacy and safety of camrelizumab-based treatment in refractory or metastatic esophageal squamous cell carcinoma. (Pubmed Central) - Feb 17, 2025
Our study has shown that camrelizumab in combination with apatinib is a promising therapy for patients with refractory or metastatic ESCC. This combination has a high response rate and favorable clinical safety.
- ||| Retrospective data, Review, Journal, Adverse events: Hepatic Adverse Events with CDK4/6 Inhibitors: A systematic review combining meta-analysis and FAERS Database. (Pubmed Central) - Feb 17, 2025
Palbociclib, ribociclib, and abemaciclib caused liver damage, while dalpiciclib did not. The most common manifestations were elevated ALT and AST levels.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Advanced pancreatic cancer treated with camrelizumab combined with apatinib: A case report. (Pubmed Central) - Feb 17, 2025
Immunotherapy and targeted therapy have the potential to increase both the quality of life and survival time of PC patients, particularly those whose tumor progression is not effectively controlled by chemotherapy alone. Nevertheless, further clinical trials are necessary to validate these findings.